Balaxi Pharmaceuticals Share Price

23.65-0.03 (-0.09%)

NSE

Closed
As On: 19 Jun, 2026, 03:54 PM IST
As On:

Sector: Miscellaneous
Industry: Miscellaneous

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	23.85
High	23.90
Low	22.50
Prev Close	23.67
Volume	22,199
VWAP(₹)	23.21

Share Price	Value
Today/Current/Last	23.65-
Previous Day	23.67-

Balaxi Pharma Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Balaxi Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	72.64	57.76	68.97	74.57	77.23
Total Income Growth (%)	25.76	-16.25	-7.52	-3.44	5.40
Total Expenses	70.01	55.49	67.06	64.17	69.78
Total Expenses Growth (%)	26.17	-17.25	4.49	-8.04	3.75
EBIT	2.63	2.27	1.91	10.40	7.45
EBIT Growth (%)	15.71	18.83	-81.64	39.64	23.83
Profit after Tax (PAT)	0.31	0.21	0.29	8.64	5.36
PAT Growth (%)	45.93	-27.96	-96.64	61.06	16.85
EBIT Margin (%)	3.61	3.93	2.77	13.94	9.64
Net Profit Margin (%)	0.42	0.36	0.42	11.58	6.94
Basic EPS (₹)	0.06	0.04	0.05	1.56	0.97

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	26.22	23.52	17.17	9.97	14.07
Total Income Growth (%)	11.45	37.01	72.22	-29.17	-37.30
Total Expenses	23.36	18.66	16.28	10.41	11.17
Total Expenses Growth (%)	25.22	14.60	56.34	-6.81	-43.54
EBIT	2.85	4.87	0.89	-0.44	2.90
EBIT Growth (%)	-41.36	447.18	-	-115.32	9.30
Profit after Tax (PAT)	1.53	3.26	0.19	-1.18	1.74
PAT Growth (%)	-53.10	1,574.50	-	-167.61	4.90
EBIT Margin (%)	10.88	20.69	5.18	-4.46	20.61
Net Profit Margin (%)	5.84	13.87	1.14	-11.82	12.39
Basic EPS (₹)	0.28	0.59	0.04	-0.21	0.32

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	288.84	238.65	339.07	284.36	233.56
Total Revenue Growth (%)	21.03	-29.62	19.24	21.75	382.13
Total Expenses	260.18	198.34	282.15	229.84	189.23
Total Expenses Growth (%)	31.18	-29.70	22.76	21.46	378.22
Profit after Tax (PAT)	25.07	-2.39	45.96	47.66	38.14
PAT Growth (%)	-	-105.19	-3.56	24.96	524.79
Operating Profit Margin (%)	10.80	17.40	17.06	19.56	19.16
Net Profit Margin (%)	8.56	-0.98	13.66	17.05	16.48
Basic EPS (₹)	4.54	-2.32	45.81	47.66	38.14

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	66.36	72.59	114.74	104.04	88.68
Total Revenue Growth (%)	-8.59	-36.73	10.29	17.32	83.06
Total Expenses	61.07	67.01	92.29	84.34	68.08
Total Expenses Growth (%)	-8.86	-27.39	9.43	23.88	73.78
Profit after Tax (PAT)	3.60	3.65	16.22	14.67	15.13
PAT Growth (%)	-1.34	-77.50	10.60	-3.08	132.97
Operating Profit Margin (%)	12.04	10.14	21.18	19.50	23.72
Net Profit Margin (%)	5.90	5.20	15.00	14.48	17.42
Basic EPS (₹)	0.65	3.55	16.17	14.67	15.13

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 1.44% of its operating revenues towards interest expenses and 14.14% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	310.34	258.34	239.67	176.47	99.68
Total Assets Growth (%)	20.13	7.79	35.81	77.04	177.11
Total Liabilities	78.61	56.98	56.79	63.31	34.70
Total Liabilities Growth (%)	37.96	0.33	-10.29	82.44	321.88
Total Equity	231.74	201.36	182.88	113.16	64.98
Total Equity Growth (%)	15.08	10.11	61.61	74.15	134.20
Current Ratio (x)	4.45	3.88	3.64	2.23	2.70
Total Debt to Equity (x)	0.22	0.09	0.06	0.03	0.06
Contingent Liabilities	-	-	-	-	-

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	174.45	154.36	129.72	81.92	68.92
Total Assets Growth (%)	13.02	18.99	58.35	18.86	81.80
Total Liabilities	46.59	32.82	37.62	24.00	25.67
Total Liabilities Growth (%)	41.96	-12.76	56.75	-6.51	162.21
Total Equity	127.85	121.55	92.11	57.91	43.25
Total Equity Growth (%)	5.18	31.96	59.06	33.90	53.86
Current Ratio (x)	2.73	4.09	2.84	2.26	1.90
Total Debt to Equity (x)	0.24	0.11	0.12	0.03	0.08
Contingent Liabilities	-	-	-	-	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	-35.00	4.87	6.08	34.14	0.00
Net Cash used in Investing Activities	-21.76	-1.05	-10.57	-28.45	-5.97
Net Cash flow from Financing Activities	33.88	30.25	25.51	-0.16	3.65
Net Cash Flow	-22.89	34.07	21.02	5.53	-2.32
Closing Cash & Cash Equivalent	39.40	62.29	28.21	7.19	1.66
Closing Cash & Cash Equivalent Growth (%)	-36.75	120.78	292.39	334.04	-58.38
Total Debt/ CFO (x)	-1.47	3.63	1.91	0.11	1,143.50

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	-7.60	-1.83	-7.07	8.89	13.46
Net Cash used in Investing Activities	-24.98	0.46	-2.29	-6.87	-20.03
Net Cash flow from Financing Activities	17.21	27.55	26.39	-1.64	3.49
Net Cash Flow	-15.37	26.19	17.03	0.38	-3.08
Closing Cash & Cash Equivalent	28.68	44.06	17.87	0.84	0.46
Closing Cash & Cash Equivalent Growth (%)	-34.89	146.51	2,024.86	81.00	-86.90
Total Debt/ CFO (x)	-4.00	-7.62	-1.52	0.22	0.26

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 20.78 cr for investing activities which is an YoY decrease of 4.52%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	10.81	-1.18	25.13	42.11	58.69
Return on Capital Employed (%)	12.35	20.56	30.78	48.28	68.23
Return on Assets (%)	8.07	-0.92	19.17	27.00	38.25
Interest Coverage Ratio (x)	11.42	26.29	118.35	389.66	3,407.65
Asset Turnover Ratio (x)	1.03	0.97	1.62	2.02	3.41
Price to Earnings (x)	14.08	-227.27	11.75	7.38	13.76
Price to Book (x)	1.52	2.68	2.95	3.11	8.07
EV/EBITDA (x)	10.90	11.25	8.84	6.31	11.79
EBITDA Margin (%)	11.45	18.26	17.58	19.74	19.29

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	2.81	3.00	17.61	25.32	34.99
Return on Capital Employed (%)	5.62	5.73	24.14	34.09	47.64
Return on Assets (%)	2.06	2.36	12.50	17.90	21.95
Interest Coverage Ratio (x)	3.79	4.95	51.03	326.96	1,573.27
Asset Turnover Ratio (x)	0.37	0.49	1.02	1.34	126.04
Price to Earnings (x)	98.04	149.25	33.33	23.98	34.72
Price to Book (x)	2.76	4.45	5.86	6.07	12.13
EV/EBITDA (x)	45.45	66.85	22.75	17.63	25.49
EBITDA Margin (%)	12.79	10.87	21.66	19.75	23.82

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Balaxi Pharma	92.14	0.52	0.56	3.10	0.42	-6.90	3.40	0.52	0.26	6.14	0.22	-12.39
Add More stocks of your interest to compare.

Annual Ratios (%)

Choose from Peers

Choose from Stocks

Stock Performance
- CHART
- TABLE
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
- Choose from Peers
  Choose from Stocks
- There’s no suggested peer for this stock.
NAME 1D 1W 1M 3M 1Y 3Y 5Y
Balaxi Pharma Stock Performance -0.09 -10.52 -13.31 17.66 -55.23 -80.68 -80.82
Add More stocks of your interest to compare.
All values in %
Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Balaxi Pharma Stock Performance	-0.09	-10.52	-13.31	17.66	-55.23	-80.68	-80.82
Add More stocks of your interest to compare.

Category	No. of Shares	Percentage	% Change QoQ
Promoters	3,64,31,770	65.99 %	0.00
Pledge	0	0.00 %	0.00
FII	26	0.00 %	-1.74
DII	14,00,537	2.54 %	-
Others	1,73,75,167	31.47 %	-0.80

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	65.99	65.99	65.99	65.99
Pledge	0.00	0.00	0.00	0.00
FII	0.00	1.74	3.50	8.86
DII	2.54	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	31.47	32.27	30.51	25.15

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results & Others
May 11, 2026
Board Meeting
Quarterly Results & Others
Jan 21, 2026
Board Meeting
Quarterly Results & Others
Nov 04, 2025

Board Meetings

Announced on	Meeting on
May 11, 2026	May 28, 2026
Audited Results & Others
Jan 21, 2026	Jan 28, 2026
Quarterly Results & Others
Nov 04, 2025	Nov 11, 2025
Quarterly Results & Others
Jul 29, 2025	Aug 05, 2025
Quarterly Results & Others
May 21, 2025	May 30, 2025
Audited Results & Others

Dividends
No Data Available
Bonus
No Data Available
Splits
Announced on Ex-Date
Feb 28, 2024 May 30, 2024
Split: Old FV10.0| New FV:2.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Aug 10, 2025 Aug 25, 2025
-
May 29, 2024 Aug 23, 2024
-
May 29, 2023 Aug 25, 2023
-
Jul 17, 2021 Aug 25, 2021
-
Aug 17, 2020 Sep 11, 2020
-

Announced on	Ex-Date
Feb 28, 2024	May 30, 2024
Split: Old FV10.0\| New FV:2.0

Announced on	Meeting on
Aug 10, 2025	Aug 25, 2025
-
May 29, 2024	Aug 23, 2024
-
May 29, 2023	Aug 25, 2023
-
Jul 17, 2021	Aug 25, 2021
-
Aug 17, 2020	Sep 11, 2020
-

About Balaxi Pharma

Balaxi Pharmaceuticals Ltd., incorporated in the year 1942, is a Small Cap company (having a market cap of Rs 130.57 Crore) operating in Miscellaneous sector.

Balaxi Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceutical Products for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 73.63 Crore, up 1.37 % from last quarter Total Income of Rs 72.64 Crore and down 1.26 % from last year same quarter Total Income of Rs 74.57 Crore. Company has reported net profit after tax of Rs .61 Crore in latest quarter.

The company’s top management includes Mr.Ashish Maheshwari, Mrs.Minoshi Maheshwari, Ms.Akshita Surana, Mr.Gandhi Gamji, Mr.Kunal Mahendra Bhakta, Mr.Mangina Srinivas Rao, Mr.Amol Mantri, Mr.Mohith Kumar Khandelwal. Company has Mohan & Ravi as its auditors. As on 31-03-2026, the company has a total of 5.52 Crore shares outstanding.

Balaxi Pharma Share Price Today is Rs. 23.65. On previous day, the Balaxi Pharma Share Price (NSE) closed at Rs. 23.56, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 65.99% of the stake in Balaxi Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Balaxi Pharma stocks was 0.0% as compared to 1.74% in Dec 2025 with decrease of 1.74%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 2.54% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Balaxi Pharma shares 0.0% was held by mutual funds. The rest including public held is 31.47%. Balaxi Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Balaxi Pharma Dividend: Ever since 1942, Balaxi Pharma dividends has been paid out around 0 times. As on 19 Jun, 2026, 03:54 PM IST, The overall dividend yield for Balaxi Pharma stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 0.26.

Balaxi Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 73.63 Cr. of sales and 1.37% of quarterly net profit, there have been multiple ups and downs in the Balaxi Pharma stock prices in the past few weeks. For example, Balaxi Pharma stock price on 11th of June 2026 was around Rs. 23.24. Balaxi Pharma share price now stands at an average of Rs. 23.65. Judging by last week's performance, stock is in up trend.

Balaxi Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Balaxi Pharma share.

Historical Prices and Performance:
Balaxi Pharma, incorporated in 1942 is a Small Cap company (with a market cap of Rs. 130.68) operating in Miscellaneous sector.
The Return of Equity (ROE) in last five financial years given by Balaxi Pharma stock was 0.56%, 10.81%, -1.18%, 25.13% and 42.11% respectively.
The Balaxi Pharma share gave a 3 year return of -77.88% as compared to Nifty 50 which gave a return of 28.38%.
Balaxi Pharma announced 0.0% final dividend on null.

Key Metrics:
PE Ratio of Balaxi Pharma is 92.22
Prices/Sales Ratio of Balaxi Pharma is 0.32
Price/Book Ratio of Balaxi Pharma is 0.52

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Balaxi Pharma, major competitors and peers include Equippp Social Impact, Metroglobal Ltd, Ruchi Infra and SE Power. As of Dec 2025, the dividend yield of Balaxi Pharma stands at 0.0% while Equippp Social Impact, Metroglobal Ltd, Ruchi Infra and SE Power stand at 0.0%, 1.96%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 92.22 and 0.52 respectively.

Leadership of Balaxi Pharma :
Amol Mantri is Chief Financial Officer
Pranav Maheshwari is Sr. Vice President - Business Development
Mohith Kumar Khandelwal is Co. Secretary & Compl. Officer
Ashish Maheshwari is Managing Director
Minoshi Maheshwari is Non Executive Director
Akshita Surana is Independent Director
Mangina Srinivas Rao is Independent Director
Gandhi Gamji is Independent Director
Kunal Mahendra Bhakta is Independent Director

Industry

Miscellaneous

Key Indices Listed On

-

Address

Plot No. 409, H. No. 8-2-293,Maps Towers, 3rd Floor, Phase - III,Road No. 81, Jubilee Hills,Hyderabad, Telangana - 500096

Contact

info@balaxi.in

https://www.balaxipharma.in

PE Ratio(x)	92.14
EPS - TTM(₹)	0.26
MCap(₹ Cr.)	130.57
MCap Rank	36
PB Ratio(x)	0.52
Div Yield(%)	-
Face Value(₹)	2.00
52W High(₹)	54.70
52W Low(₹)	15.20
MCap/Sales	0.32
Beta(1 Month)	1.68
BV/Share(₹)	45.12

1 Day	-0.09%
1 Month	-3.07%
3 Months	31.24%
1 Year	-52.13%
3 Years	-77.77%
5 Years	-80.26%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Balaxi Pharmaceuticals Share Price

Key Metrics

Balaxi Pharma share price insights

Balaxi Pharma Share Price Returns

Balaxi Pharma Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Balaxi Pharma Top Searches

Corporate Actions

About Balaxi Pharma

Executive Leadership

Auditors

FAQs about Balaxi Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News